The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Srdan Verstovsek

Department of Leukemia

The University of Texas

MD Anderson Cancer Center

Houston

USA

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, USA. 2006 - 2013
  • UT M.D. Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd., U.S.A. 2011 - 2012
  • Department of Hematology, University Hospital Merkur, University of Zagreb School of Medicine, Zagreb, Croatia. 2011

References

  1. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Verstovsek, S. Eur. J. Haematol. (2013) [Pubmed]
  2. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V., Kantarjian, H.M. Br. J. Haematol. (2013) [Pubmed]
  3. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Verstovsek, S., Kantarjian, H.M., Estrov, Z., Cortes, J.E., Thomas, D.A., Kadia, T., Pierce, S., Jabbour, E., Borthakur, G., Rumi, E., Pungolino, E., Morra, E., Caramazza, D., Cazzola, M., Passamonti, F. Blood (2012) [Pubmed]
  4. JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation? Santos, F.P., Verstovsek, S. Anticancer. Agents. Med. Chem (2012) [Pubmed]
  5. Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. Randhawa, J., Ostojic, A., Vrhovac, R., Atallah, E., Verstovsek, S. J. Hematol. Oncol (2012) [Pubmed]
  6. The Organic Arsenic Derivative GMZ27 Induces PML-RARα-Independent Apoptosis in Myeloid Leukemia Cells. Cheng, X., Quintás-Cardama, A., Golemovic, M., Zingaro, R., Gao, M.Z., Freireich, E.J., Andreeff, M., Kantarjian, H.M., Verstovsek, S. Anticancer Res. (2012) [Pubmed]
  7. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V., Kantarjian, H.M. N. Engl. J. Med. (2012) [Pubmed]
  8. Ruxolitinib for the treatment of myelofibrosis. Ostojic, A., Vrhovac, R., Verstovsek, S. Drugs. Today (2011) [Pubmed]
  9. New JAK2 inhibitors for myeloproliferative neoplasms. Quintás-Cardama, A., Verstovsek, S. Expert. Opin. Investig. Drugs (2011) [Pubmed]
  10. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. Verstovsek, S., Kantarjian, H., Mesa, R.A., Pardanani, A.D., Cortes-Franco, J., Thomas, D.A., Estrov, Z., Fridman, J.S., Bradley, E.C., Erickson-Viitanen, S., Vaddi, K., Levy, R., Tefferi, A. N. Engl. J. Med. (2010) [Pubmed]
  11. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Verstovsek, S. Clin. Cancer Res. (2010) [Pubmed]
  12. Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders. Verstovsek, S. Leuk. Res. (2009) [Pubmed]
  13. Therapeutic potential of JAK2 inhibitors. Verstovsek, S. Hematology. Am. Soc. Hematol. Educ. Program (2009) [Pubmed]
  14. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Verstovsek, S., Tefferi, A., Kantarjian, H., Manshouri, T., Luthra, R., Pardanani, A., Quintás-Cardama, A., Ravandi, F., Ault, P., Bueso-Ramos, C., Cortes, J.E. Clin. Cancer Res. (2009) [Pubmed]
  15. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Verstovsek, S., Tefferi, A., Cortes, J., O'Brien, S., Garcia-Manero, G., Pardanani, A., Akin, C., Faderl, S., Manshouri, T., Thomas, D., Kantarjian, H. Clin. Cancer Res. (2008) [Pubmed]
  16. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Verstovsek, S., Giles, F., Quintás-Cardama, A., Perez, N., Ravandi-Kashani, F., Beran, M., Freireich, E., Kantarjian, H. Hematol. Oncol (2006) [Pubmed]
  17. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Verstovsek, S., Giles, F.J., Quintás-Cardama, A., Manshouri, T., Huynh, L., Manley, P., Cortes, J., Tefferi, A., Kantarjian, H. Leuk. Res. (2006) [Pubmed]
  18. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Verstovsek, S., Akin, C., Manshouri, T., Quintás-Cardama, A., Huynh, L., Manley, P., Tefferi, A., Cortes, J., Giles, F.J., Kantarjian, H. Leuk. Res. (2006) [Pubmed]
 
WikiGenes - Universities